Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people living with HIV-1, focusing on improving the current standard of care. The study compares a new once-weekly antiretroviral therapy ART combining islatravir and ulonivirine to the standard daily ART regimen, which includes multiple medications taken up to twice a day. This research aims to evaluate if the new study ART works as well as the current standard treatment, while also assessing its safety and how well participants tolerate it. Participants will be randomly assigned to one of several groups one group will receive the study drugs islatravir and ulonivirine once weekly, another will take the standard ART daily, and two additional groups will receive combinations of study drugs and placebos for 96 weeks. The study involves both phase 2 and phase 3 parts, with participants taking their assigned medication orally either once daily or once weekly during this period. Throughout the study, participants will attend regular visits for up to 96 weeks where researchers will monitor their HIV-1 RNA levels, CD4 T-cell counts, body weight, and any adverse events. The main measurement is the percentage of participants with HIV-1 RNA below 50 copiesmL at weeks 24 and 48 for phase 2 and phase 3 respectively. Safety and tolerability will also be closely observed, including any discontinuation due to adverse events. Participants health will be followed through various laboratory tests and assessments during the study period.
Actively Recruiting
Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.
Actively Recruiting
This research aims to evaluate a behavioral intervention called Behavioral Exposure for Interoceptive Tolerance BE-FIT designed to reduce exercise anxiety in patients undergoing cardiac rehabilitation. The study is a Stage II randomized-controlled trial involving individuals aged 40 and older who have elevated exercise anxiety and are enrolled in a cardiac rehabilitation program. The goal is to determine whether BE-FIT improves exercise adherence and to understand the mechanisms behind any changes in physical activity behavior. Participants will be randomly assigned to one of two groups the BE-FIT intervention group or a health education control HEC group. BE-FIT includes six 45-minute individual sessions over three weeks, focusing on exposure to feared bodily sensations and exercise, preventing safety behaviors around exercise, and using a wrist-worn activity monitor Fitbit for feedback and goal setting. The HEC group receives time-matched educational sessions on healthy aging topics and also uses the Fitbit for monitoring physical activity but without set activity goals. Over 24 weeks, participants will engage in six sessions delivered twice weekly alongside their cardiac rehabilitation program. Data collection includes five assessments at baseline, end of treatment, and follow-ups at weeks 12, 18, and 24. Researchers will measure overall exercise minutes, attendance at cardiac rehabilitation, and daily steps. The study involves monitoring through questionnaires, Fitbit data, and clinical supervision to assess changes in exercise anxiety and adherence.
Actively Recruiting
The trial follows adults aged 20 to 70 with chronic hepatitis B CHB who previously received the investigational drug imdusiran and stopped nucleostide analog NA therapy during that earlier study. It aims to evaluate how long the effects of imdusiran on hepatitis B virus HBV parameters last over time. This observational study involves no new treatments and focuses on long-term monitoring. Participants enroll after completing their prior imdusiran trial and remain off NA therapy. The study involves no interventions beyond collecting blood samples, reviewing current medications, and recording any adverse events related to study procedures or if NA therapy is restarted. There are no additional study treatments. Participants will be followed for about 2 years to complete at least 3 years of follow-up since stopping NA therapy, including time in the parent study. Researchers will assess HBV markers to measure imdusirans lasting effect. Regular blood tests and medication reviews will monitor safety and disease status during the study.